These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 25313760)
1. Serum ferritin is elevated in advanced non-small cell lung cancer patients and is associated with efficacy of platinum-based chemotherapy. Shi HB; Li XD; Jiang JT; Zhao WQ; Ji M; Wu CP J Cancer Res Ther; 2014; 10(3):681-5. PubMed ID: 25313760 [TBL] [Abstract][Full Text] [Related]
2. Excision-repair-cross-complement-1 protein as a prognostic factor in patients with advanced non-small cell lung cancer treated with platinum-based first-line chemotherapy. Vassalou H; Stathopoulos E; Fiolitaki G; Koutsopoulos A; Voutsina A; Georgoulias V; Mavroudis D Lung Cancer; 2013 Nov; 82(2):324-9. PubMed ID: 23993732 [TBL] [Abstract][Full Text] [Related]
3. Serum vascular endothelial growth factor (VEGF) and bcl-2 levels in advanced stage non-small cell lung cancer. Tas F; Duranyildiz D; Oguz H; Camlica H; Yasasever V; Topuz E Cancer Invest; 2006 Oct; 24(6):576-80. PubMed ID: 16982461 [TBL] [Abstract][Full Text] [Related]
4. Survival rates and tolerability of platinum-based chemotherapy regimens for elderly patients with non-small-cell lung cancer (NSCLC). Costa GJ; Fernandes AL; Pereira JR; Curtis JR; Santoro IL Lung Cancer; 2006 Aug; 53(2):171-6. PubMed ID: 16757059 [TBL] [Abstract][Full Text] [Related]
5. [Comparison of treatment efficacy of the second and the third generations of chemoradiotherapy regimens containing platinum on advanced non-small cell lung cancer]. Wang YM; Guo LJ; Li LS; Li P; Zheng J; Li L Ai Zheng; 2005 Dec; 24(12):1514-7. PubMed ID: 16351804 [TBL] [Abstract][Full Text] [Related]
6. Osteopontin expression is associated with platinum-based chemotherapy response and prognosis of patients with advanced non small cell lung cancer. Zhang T; Zhang DM; Zhao D; Hou XM; Yang TN J BUON; 2014; 19(3):742-8. PubMed ID: 25261661 [TBL] [Abstract][Full Text] [Related]
7. [Prognostic significance of ERCC1 mRNA expression in patients with non-small cell lung cancer receiving platinum-based chemotherapy]. Qian XP; Liu BR; Shi MQ; Liu XZ; Hu WJ; Zou ZY; Wei J Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):33-7. PubMed ID: 19538866 [TBL] [Abstract][Full Text] [Related]
8. Serum APE1 as a predictive marker for platinum-based chemotherapy of non-small cell lung cancer patients. Zhang S; He L; Dai N; Guan W; Shan J; Yang X; Zhong Z; Qing Y; Jin F; Chen C; Yang Y; Wang H; Baugh L; Tell G; Wilson DM; Li M; Wang D Oncotarget; 2016 Nov; 7(47):77482-77494. PubMed ID: 27813497 [TBL] [Abstract][Full Text] [Related]
9. Brief report: retrospective review of efficacy of erlotinib or gefitinib compared to docetaxel as subsequent line therapy in advanced non-small cell lung cancer (NSCLC) following failure of platinum-based chemotherapy. Ng R; Loreto M; Lee R; Leighl NB Lung Cancer; 2008 Aug; 61(2):262-5. PubMed ID: 18358559 [TBL] [Abstract][Full Text] [Related]
10. Retrospective evaluation of thromboembolic events in patients with non-small cell lung cancer treated with platinum-based chemotherapy. Mellema WW; van der Hoek D; Postmus PE; Smit EF Lung Cancer; 2014 Oct; 86(1):73-7. PubMed ID: 25129368 [TBL] [Abstract][Full Text] [Related]
11. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients. Zhou C; Ren S; Zhou S; Zhang L; Su C; Zhang Z; Deng Q; Zhang J Jpn J Clin Oncol; 2010 Oct; 40(10):954-60. PubMed ID: 20462983 [TBL] [Abstract][Full Text] [Related]
12. Novel association between CD74 polymorphisms and hematologic toxicity in patients with NSCLC after platinum-based chemotherapy. Tan X; Wu Q; Cai Y; Zhao X; Wang S; Gao Z; Yang Y; Li X; Qian J; Wang J; Su B; Chen H; Han B; Jiang G; Lu D Clin Lung Cancer; 2014 Jan; 15(1):67-78.e12. PubMed ID: 24220096 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Ciuleanu T; Stelmakh L; Cicenas S; Miliauskas S; Grigorescu AC; Hillenbach C; Johannsdottir HK; Klughammer B; Gonzalez EE Lancet Oncol; 2012 Mar; 13(3):300-8. PubMed ID: 22277837 [TBL] [Abstract][Full Text] [Related]
14. [Effect of pemetrexed plus platinum for chemotherapy-naive advanced non-small cell lung cancer]. Duan JC; Wu MN; Zhao J; An TT; Yang L; Bai H; Wang ZJ; Zhuo ML; Wang SH; Wang YY; Liu XH; Wang J Zhonghua Jie He He Hu Xi Za Zhi; 2012 Feb; 35(2):97-101. PubMed ID: 22455964 [TBL] [Abstract][Full Text] [Related]
15. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy. Li Z; Qing Y; Guan W; Li M; Peng Y; Zhang S; Xiong Y; Wang D Cancer Chemother Pharmacol; 2014 Oct; 74(4):777-86. PubMed ID: 25107571 [TBL] [Abstract][Full Text] [Related]
16. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I. Ramlau R; Zatloukal P; Jassem J; Schwarzenberger P; Orlov SV; Gottfried M; Pereira JR; Temperley G; Negro-Vilar R; Rahal S; Zhang JK; Negro-Vilar A; Dziewanowska ZE J Clin Oncol; 2008 Apr; 26(11):1886-92. PubMed ID: 18398154 [TBL] [Abstract][Full Text] [Related]
17. Phase II study of epirubicin in combination with weekly docetaxel for patients with advanced NSCLC who have failed or relapsed after the frontline platinum-based chemotherapy. Lin CM; Chen CH; Chang JW; Tsao TC Am J Clin Oncol; 2009 Apr; 32(2):169-73. PubMed ID: 19307958 [TBL] [Abstract][Full Text] [Related]
18. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744 [TBL] [Abstract][Full Text] [Related]
19. Paclitaxel/Platinum-based perioperative chemotherapy and surgery in stage IIIA non-small cell lung cancer. Choi IS; Oh DY; Kwon JH; Kim SI; Park SR; Bak JY; Kim JH; Kim DW; Kim YT; Kim TY; You CK; Kim YW; Heo DS; Bang YJ; Sung SW; Park CI; Kim NK Jpn J Clin Oncol; 2005 Jan; 35(1):6-12. PubMed ID: 15681597 [TBL] [Abstract][Full Text] [Related]
20. Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease. Kenmotsu H; Naito T; Mori K; Ko R; Ono A; Wakuda K; Imai H; Taira T; Murakami H; Endo M; Takahashi T Cancer Chemother Pharmacol; 2015 Mar; 75(3):521-6. PubMed ID: 25563718 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]